Fulcrum Therapeutics (FULC) Stock Forecast & Price Target

Compare

493 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

FULC Analyst Ratings

Moderate Buy

4 Buy

2 Hold

1 Sell

Based on 7 analysts giving stock ratings to

Fulcrum

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

FULC Stock 12 Month Forecast

Average Price Target

$7.57

▲(9.71%Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $7.57 with a high forecast of $12.00 and a low forecast of $2.00. The average price target represents a 9.71% change from the last price of $6.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","10":"$10","13":"$13"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4,7,10,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2024","6":"Jul<br/>2024","9":"Oct<br/>2024","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.38,4.966153846153846,5.552307692307692,6.138461538461538,6.724615384615385,7.31076923076923,7.896923076923077,8.483076923076922,9.069230769230769,9.655384615384616,10.241538461538461,10.827692307692306,11.413846153846155,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.38,4.625384615384616,4.8707692307692305,5.116153846153846,5.361538461538462,5.606923076923077,5.852307692307693,6.0976923076923075,6.343076923076923,6.588461538461539,6.833846153846154,7.07923076923077,7.3246153846153845,{"y":7.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.38,4.196923076923077,4.013846153846154,3.8307692307692305,3.6476923076923073,3.464615384615384,3.2815384615384615,3.0984615384615384,2.9153846153846152,2.732307692307692,2.549230769230769,2.366153846153846,2.183076923076923,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.61,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.21,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.02,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.99,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.31,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.01,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.21,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$12.00

Average Price Target$7.57

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

1.45%

Upside

Reiterated

05/16/25

Fulcrum Therapeutics is positioned with strong revenue stability and an impressive gross profit margin, supported by a solid balance sheet with low leverage. Despite these strengths, the company faces challenges with profitability and cash flow sustainability. The stock is experiencing strong technical momentum, but caution is warranted due to overbought indications. Valuation remains a concern due to ongoing losses and a negative P/E ratio. Positive sentiment from the earnings call and progress in clinical trials is offset by the negative impact of the terminated agreement with MyoKardia. Overall, the stock scores moderately, balancing its strengths in financial stability and technical momentum against its valuation and operational challenges.

Edward TenthoffPiper Sandler

Piper Sandler

$6→$9

Buy

30.43%

Upside

Reiterated

05/29/25

Piper Sandler Remains a Buy on Fulcrum Therapeutics (FULC)

Joseph SchwartzLeerink Partners

Leerink Partners

$4→$12

Buy

73.91%

Upside

Upgraded

05/23/25

Fulcrum Therapeutics upgraded to Outperform from Market Perform at LeerinkFulcrum Therapeutics upgraded to Outperform from Market Perform at Leerink

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-71.01%

Downside

Reiterated

05/19/25

Bank of America Securities Reaffirms Their Sell Rating on Fulcrum Therapeutics (FULC)

Matthew BieglerOppenheimer

Oppenheimer

$12

Buy

73.91%

Upside

Reiterated

05/16/25

Analysts' Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), Fulcrum Therapeutics (FULC)

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$10

Buy

44.93%

Upside

Upgraded

05/15/25

Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldFulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

Andrew FeinH.C. Wainwright

H.C. Wainwright

Hold

-42.03%

Downside

Reiterated

05/02/25

Hold Rating for Fulcrum Therapeutics Amid Promising Trials and Competitive Challenges

Gregory RenzaRBC Capital

RBC Capital

Hold

-42.03%

Downside

Reiterated

05/01/25

RBC Capital Sticks to Its Hold Rating for Fulcrum Therapeutics (FULC)

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$22→$3

Hold

-56.52%

Downside

Reiterated

09/26/24

Fulcrum Therapeutics (FULC) Gets a Hold from Stifel Nicolaus

Corinne JohnsonGoldman Sachs

Goldman Sachs

―

Buy

―

Reiterated

07/31/24

Fulcrum Therapeutics: A Strong Buy on Accelerated Clinical Progress and Strategic Focus

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

Hold

1.45%

Upside

Reiterated

05/16/25

Edward TenthoffPiper Sandler

Piper Sandler

$6→$9

Buy

30.43%

Upside

Reiterated

05/29/25

Piper Sandler Remains a Buy on Fulcrum Therapeutics (FULC)

Joseph SchwartzLeerink Partners

Leerink Partners

$4→$12

Buy

73.91%

Upside

Upgraded

05/23/25

Fulcrum Therapeutics upgraded to Outperform from Market Perform at LeerinkFulcrum Therapeutics upgraded to Outperform from Market Perform at Leerink

Tazeen AhmadBank of America Securities

Bank of America Securities

Sell

-71.01%

Downside

Reiterated

05/19/25

Bank of America Securities Reaffirms Their Sell Rating on Fulcrum Therapeutics (FULC)

Matthew BieglerOppenheimer

Oppenheimer

$12

Buy

73.91%

Upside

Reiterated

05/16/25

Analysts' Top Healthcare Picks: Bicara Therapeutics Inc. (BCAX), Fulcrum Therapeutics (FULC)

Kristen KluskaCantor Fitzgerald

Cantor Fitzgerald

$10

Buy

44.93%

Upside

Upgraded

05/15/25

Fulcrum Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldFulcrum Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald

Andrew FeinH.C. Wainwright

H.C. Wainwright

Hold

-42.03%

Downside

Reiterated

05/02/25

Hold Rating for Fulcrum Therapeutics Amid Promising Trials and Competitive Challenges

Gregory RenzaRBC Capital

RBC Capital

Hold

-42.03%

Downside

Reiterated

05/01/25

RBC Capital Sticks to Its Hold Rating for Fulcrum Therapeutics (FULC)

Dae Gon HaStifel Nicolaus

Stifel Nicolaus

$22→$3

Hold

-56.52%

Downside

Reiterated

09/26/24

Fulcrum Therapeutics (FULC) Gets a Hold from Stifel Nicolaus

Corinne JohnsonGoldman Sachs

Goldman Sachs

―

Buy

―

Reiterated

07/31/24

Fulcrum Therapeutics: A Strong Buy on Accelerated Clinical Progress and Strategic Focus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Fulcrum Therapeutics

1 Month

xxx

Success Rate

8/10 ratings generated profit

Average Return

+8.18%

reiterated a xxx

rating 24 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +8.18% per trade.

3 Months

xxx

Success Rate

6/11 ratings generated profit

Average Return

+29.81%

reiterated a xxx

rating 14 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +29.81% per trade.

1 Year

Matthew BieglerOppenheimer

Success Rate

8/14 ratings generated profit

Average Return

+35.81%

reiterated a buy rating 27 days ago

Copying Matthew Biegler's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +35.81% per trade.

2 Years

xxx

Success Rate

7/14 ratings generated profit

Average Return

+19.28%

reiterated a xxx

rating 27 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +19.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

FULC Analyst Recommendation Trends

Rating

Sep 24

Oct 24

Nov 24

Feb 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, FULC has received 9 Buy Ratings, 9 Hold Ratings, and 2 Sell Ratings. FULC average Analyst price target in the past 3 months is 7.57.

Each month's total comprises the sum of three months' worth of ratings.

FULC Financial Forecast

FULC Earnings Forecast

Next quarter’s earnings estimate for FULC is -$0.29 with a range of -$0.31 to -$0.28. The previous quarter’s EPS was -$0.28. FULC beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year FULC has Outperformed its overall industry.

FULC Sales Forecast

Next quarter’s sales forecast for FULC is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. FULC beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year FULC has Outperformed its overall industry.

FULC Stock Forecast FAQ

What is FULC’s average 12-month price target, according to analysts?

Based on analyst ratings, Fulcrum Therapeutics’s 12-month average price target is 7.57.

What is FULC’s upside potential, based on the analysts’ average price target?

Fulcrum Therapeutics has 9.71% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is FULC a Buy, Sell or Hold?

Fulcrum Therapeutics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 1 sell ratings.

What is Fulcrum Therapeutics’s price target?

The average price target for Fulcrum Therapeutics is 7.57. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $2.00. The average price target represents 9.71% Increase from the current price of $6.9.

What do analysts say about Fulcrum Therapeutics?

Fulcrum Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of FULC?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Fulcrum Therapeutics (FULC) Stock Forecast & Price Target

FULC Analyst Ratings

FULC Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Fulcrum Therapeutics

FULC Analyst Recommendation Trends

FULC Financial Forecast

FULC Earnings Forecast

FULC Sales Forecast

FULC Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts